LUCD · Lucid Diagnostics Inc.
$0.97
+0.00 (+0.29%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$196.68M
Shares
203.24M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.97
Open$0.97
Day$0.96–1.00
52W close$0.87–1.47
Avg vol 30d1.4M
Short int12.1M · 6.0% float · 8.3d
Short vol68%
Last earningsAug 13, 2026
DataOct 2021–Aug 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−14%
below
Price vs 50-day avg
−2%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
16%
mid-range
Momentum
relative strength
1-month return
+2%
trailing
6-month return
−32%
trailing
YTD return
−11%
this year
Relative strength
−46%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+11% holders QoQ · +24 funds added
Insider flow
Accumulating
Net +$245.3K over 90 days · 0% sells
Short interest
Rising
5.97% of float · ▲ +11.3% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
114 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+79%
Y/Y
Gross margin
9%
contracting
EPS growth
+17%
Y/Y
Free cash flow
$-46.7M
Balance sheet
$9.1M
net cash
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−41%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−14%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
16%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+11% holders QoQ · +24 funds added
Insider flow
Accumulating
Net +$245.3K over 90 days · 0% sells
Short interest
Rising
5.97% of float · ▲ +11.3% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
114 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 16%
Range high $1
vs 200-day avg -14%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| EBITDA non-GAAP | -$11.54M | three months ended June 30, 2026 | — |
|
|
|||
| Non-GAAP adjusted (loss) non-GAAP | -$10.85M | three months ended June 30, 2026 | — |
|
|
|||
| Non-GAAP adjusted (loss) income per share non-GAAP | -$0.06 | three months ended June 30, 2026 | — |
|
|
|||
| proforma cash | $45M | 1Q26 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LUCD
this stock
Lucid Diagnostics Inc.
|
$196.68M | -11.2% | +79.0% | — | 6.0% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LUCD | +0.1% | +1.9% | -32.3% | +11.0% | -11.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -0.3% | -2.6% | -46.1% | +7.1% | -25.1% |
Key facts
CIK
1799011
CUSIP
54948X109
13F (30d)
110 filings
110 filers
Visit website
Investor relations